

RECEIVED

MAY 07 2001

AP/1645
#8



TECH CENTER 1600/2900

Please type a plus sign (+) inside this box → +

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

		Application Number	09/668,558
		Filing Date	September 22, 2000
		First Named Inventor	Frances YEN, et al.
		Group Art Unit	1645
		Examiner Name	Unassigned
Total Number of Pages in This Submission		Attorney Docket Number	70.US2.REG

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	John Lucas, Ph.D., J.D. GENSET CORPORATION	Reg. No. 43,373
Signature		
Date	30 Apr 01	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: APRIL 30, 2001

Typed or printed name	C. M. McClure	Date	04/30/2001
Signature			

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Docket/Matter No. 70.US2.REG

Hf

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Applicant : Frances YEN, et al.

RECEIVED

MAY 07 2001

Appl. No. : 09/668,558

) Grp./A.U. : 1645

Filed : September 22, 2000

) TECH CENTER 1600/2900

) Examiner : Unassigned

Title : METHODS OF SCREENING FOR
COMPOUNDS THAT MODULATE THE LSR-
LEPTIN INTERACTION AND THEIR USE IN
THE PREVENTION AND TREATMENT OF
OBESITY AND RELATED DISEASES

Honorable Commissioner of Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits the references listed on the attached forms PTO/SB/08A and 08B, copies of which are enclosed. This statement is being filed before the receipt of a first Office Action on the merits.

The Commissioner is hereby authorized to charge any fees in connection with this document to our Deposit Account No.: 50-1181

Respectfully submitted,
GENSET CORPORATION

Date: 30 April, 2001

By: John Lucas
John Lucas, Ph.D., J.D.
Registration No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (858) 597-2600
Facsimile: (858) 597-2601

e-mail: john.lucas@genxy.com

Certificate of Mailing under 37 CFR 1.10

Date of Deposit: APRIL 30, 2001


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, on the Date of Deposit shown above, postage prepaid and in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

C. M. McClure

Signature

C. M. McClure

Typed or Printed Name of Person Signing Certificate



MAY 04 2002

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Approved for use through 10/01/2002. GMD 3501-000.
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/668,558
		Filing Date	September 22, 2000
		First Named Inventor	Frances YEN, et al.
		Group Art Unit	Unknown
		Examiner Name	Unassigned
		Attorney Docket Number	70.US2.REG
Sheet	1	of	3

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1600/2900

MAY 07 2001

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	09/668,558
Filing Date	September 22, 2000
First Named Inventor	Frances YEN, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	70.US2.REG

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D	C	Baskin, D.G., et al., "LEPTIN RECEPTOR mRNA IDENTIFIES A SUBPOPULATION OF NEUROPEPTIDE Y NEURONS ACTIVATED BY FASTING IN RAY HYPOTHALAMUS", (1999) Diabetes 48 :828-833	
	D	Bihain, B.E., et al., "THE LIPOLYSIS STIMULATED RECEPTOR: A GENE AT LAST", (1998) Curr. Opinion in Lip. 9(3):221-224	
	E	Campfield, L.A., et al., "RECOMBINANT MOUSE OB PROTEIN: EVIDENCE FOR A PERIPHERAL SIGNAL LINKING ADIPOSITY AND CENTRAL NEURAL NETWORKS", (1995) Science 269:546-549	
	F	Cheung, C.C., et al., "PROOPiomelanocortin NEURONS ARE DIRECTED TARGETS FOR LEPTIN IN THE HYPOTHALAMUS", (1997) Endocrinology 138:4489-4492	
	G	Considine, R.V., et al., "SERUM IMMUNOREACTIVE-LEPTIN CONCENTRATIONS IN NORMAL-WEIGHT AND OBESE HUMANS", (1996) New Eng J Med 334 :292-295	
	H	Ghebrehiwet, et al., "ISOLATION, cDNA CLONING, AND OVEREXPRESSION OF A 33-kD CELL SURFACE GLYCOPROTEIN THAT BINDS TO THE GLOBULAR 'HEADS' OF C1q", J. Exp. Med., 179:1809-1821; June 1994 (The Rockefeller University Press)	
	I	Hayward, et al., "THE cDNA SEQUENCING OF HUMAN ENDOTHELIAL CELL MULTIMERIN", J. Biol. Chem., Vol. 270, No. 31:18246-18251, August 4, 1995 (The American Society for Biochemistry and Molecular Biology, Inc.)	
	J	Hu, et al., "AdipoQ IS A NOVEL ADIPOSE-SPECIFIC GENE DYSREGULATED IN OBESITY", J. Biol. Chem. Vol. 271, No. 18:10697-10703 (May 3, 1996)	
	K	Kopelman, P.G., "OBESITY AS A MEDICAL PROBLEM", (2000) Nature 404:635-643	
	L	Maeda, et al., "cDNA CLONING AND EXPRESSION OF A NOVEL ADIPOSE SPECIFIC COLLAGEN-LIKE FACTOR, apM1 (ADIPOSE MOST ABUNDANT GENE TRANSCRIPT 1)", Biochem. and Biophys. Research Comm. 221:286-289, 1996 (Academic Press)	
	M	Mann, C. J., et al., "MECHANISM OF ACTIVATION AND FUNCTIONAL SIGNIFICANCE OF THE LIPOLYSIS-STIMULATED RECEPTOR, EVIDENCE FOR A ROLE AS CHYLOMICRON REMNANT RECEPTOR", Biochemistry, 34:10421-10431 (1995)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

三

Sheet 3 of 3

Complete if Known	
Application Number	09/668,558
Filing Date	September 22, 2000
First Named Inventor	Frances YEN, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	70.US2.REG

MAY 07 2001

EXTRA

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D	N	Mann, et al., "ApoCIII INHIBITS THE BINDING OF TRIGLYCERIDE-RICH LIPOPROTEINS TO THE LIPOLYSIS STIMULATED RECEPTOR", Abstract (1996)	
	O	Schwartz, M.W., et al., "CENTRAL NERVOUS SYSTEM CONTROL OF FOOD INTAKE", (2000) Nature 404 :661-671	
	P	Schwartz, M.W., et al., "CEREBROSPINAL FLUID LEVELS: RELATIONSHIP TO PLASMA LEVELS AND TO ADIPOSITY IN HUMANS", (1996) Nature Med 2 :589-593	
	Q	Sellar, et al., "CHARACTERIZATION AND ORGANIZATION OF THE GENES ENCODING THE A-, B- AND C-CHAINS OF HUMAN COMPLEMENT SUBCOMPONENT C1q", Biochemical Journal, 274:481-490 (1991)	
	R	Troussard, A.A., et al., "INHIBITORY EFFECT ON THE LIPOLYSIS-STIMULATED RECEPTOR OF THE 39-kDa RECEPTOR-ASSOCIATED PROTEIN", Jr. of Biol. Chem., Vol. 270, #29:17068-71, July 21, 1995 (The American Society for Biochemistry and Molecular Biology, Inc.)	
	S	Urade, Y., et al., "PRECEREBELLIN IS A CEREBELLUM-SPECIFIC PROTEIN WITH SIMILARITY TO THE GLOBULAR DOMAIN OF COMPLEMENT C1qB CHAIN", Proc. Natl. Sci. USA, 88:1069-1073, February, 1991	
	T	Weigle, D.S., et al., "RECOMBINANT OB PROTEIN REDUCES FEEDING AND BODY WEIGHT IN THE OB/OB MOUSE", (1995) J. Clin. Invest. 96:2065-2070	
	U	Zhang, Y., et al., "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE", (1994) Nature 372:425-432	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Previous citation designation number. **2** Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.